Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc

Antiviral Research

Volumn 86, Issue 2, 2010, Pages 224-226

  Armstrong James, Darius ^a   Stebbing, Justin ^a   Scourfield, Andrew ^a   Smit, Erasmus ^a   Ferns, Bridget ^a   Pillay, Deenan ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Genotyping; HIV 2; Maraviroc; Outcome; Raltegravir

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; TENOFOVIR;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; COGNITIVE DEFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MALE; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; TOXOPLASMOSIS; VIRUS ENCEPHALITIS; VIRUS LOAD;

ANTI-HIV AGENTS; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-2; HUMANS; PYRROLIDINONES; RNA, VIRAL; TREATMENT OUTCOME; TRIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 77951298322     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.02.324     Document Type: Article

References (17)

1. Adjé-Touré C.A., Cheingsong R., Garcìa-Lerma J.G., Eholié S., Borget M.Y., Bouchez J.M., Otten R.A., Maurice C., Sassan-Morokro M., Ekpini R.E., Nolan M., Chorba T., Heneine W., Nkengasong J.N. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003, 17(Suppl (3)):S49-S54.
2. De Clercq E. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 1993, 13:229-258.
3. Garrett N., Xu L., Smit E., Ferns B., El-Gadi S., Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 2008, 22:1091-1092.
4. Gottlieb G., Eholié S., Nkengasong J.N., Jallow S., Rowland-Jones S., Whittle H.C., Sow P.S. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008, 22:2069-2072. (discussion 2073-2074).
5. Guillon C., van der Ende M.E., Boers P.H., Gruters R.A., Schutten M., Osterhaus A.D. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. J. Virol. 1998, 72:6260-6263.
6. Gustchina A., Weber I.T. Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 1991, 10:325-339.
7. Leligdowicz A., Rowland-Jones S. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection. Expert Rev. Vaccines 2008, 7:319-331.
8. Matheron S., Damond F., Benard A., Taieb A., Campa P., Peytavin G., Pueyo S., Brun-Vézinet F., Chene G. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006, 20:459-462. ANRS CO5 HIV-2 Cohort Study Group.
9. McKnight A., Dittmar M.T., Moniz-Periera J., Ariyoshi K., Reeves J.D., Hibbitts S., Whitby D., Aarons E., Proudfoot A.E., Whittle H., Clapham P.R. A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J. Virol. 1998, 72:4065-4071.
10. Ntemgwa M., Brenner B.G., Oliveira M., Moisi D., Wainberg M.A. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents Chemother. 2007, 51:604-610.
11. Ohtaka H., Freire E. Adaptive inhibitors of the HIV-1 protease. Prog. Biophys. Mol. Biol. 2005, 88(2):193-208.
12. Ren J., Bird L.E., Chamberlain P.P., Stewart-Jones G.B., Stuart D.I., Stammers D.K. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA 2002, 99:14410-14415.
13. Roquebert B., Damond F., Collin G., Matheron S., Peytavin G., Bénard A., Campa P., Chene G., Brun-Vézinet F., Descamps D. French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)., HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J. Antimicrob. Chemother. 2008, 62:914-920.
14. Ruelle J., Roman F., Vandenbroucke A.T., Lambert C., Fransen K., Echahidi F., Piérard D., Verhofstede C., Van Laethem K., Delforge M.L., Vaira D., Schmit J.C., Goubeau P. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect. Dis. 2008, 8:21.
15. Smith R.A., Gottlieb G.S., Anderson D.J., Pyrak C.L., Preston B.D. Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob. Agents Chemother. 2008, 52:329-332.
16. Soares R., Foxall R., Albuquerque A., Cortesão C., Garcia M., Victorino R.M., Sousa A.E. Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection. J. Virol. 2006, 80:12425-12429.
17. van der Ende M.E., Prins J.M., Brinkman K., Keuter M., Veenstra J., Danner S.A., Niesters H.G., Osterhaus A.D., Schutter M. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003, 17(Suppl. (3)):S55-S61.